Directory
>
Rachel Humphrey Md
Rachel Humphrey Md
Independent Board Director | HotSpot Therapeutics, Inc.
Boston, Massachusetts, United States
Rachel Humphrey Md
Summary
Rachel Humphrey, MD, is a distinguished pharmaceutical executive with over 18 years of experience in product development and clinical research, particularly in oncology and immuno-oncology. As the President and Founding CEO of Normunity, she has a proven track record in leading teams to successfully develop and commercialize new molecular entities, including the renowned drugs NEXAVAR and YERVOY. Rachel has held significant leadership roles at major pharmaceutical companies such as AstraZeneca and Bristol Myers Squibb, where she has been instrumental in shaping product strategies and overseeing global development programs. Her expertise spans from early-stage clinical trials to post-launch activities, and she has extensive experience in regulatory interactions and alliance management. Rachel's academic background includes a medical degree from Case Western Reserve University and a residency at Johns Hopkins University, underscoring her deep commitment to medical science. She is also known for her strategic insights and ability to foster collaborations between large and small biotech firms, contributing to advancements in cancer treatment.
Rachel Humphrey Md
Work Experience
Independent Board Director at
Pyxis Oncology
August 2022 - Present
Scientific Advisory Board Member at
Grey Wolf Therapeutics
December 2021 - Present
President and Founding CEO at
Normunity
October 2021 - Present
Scientific Advisory Board Member at
HotSpot Therapeutics, Inc.
October 2021 - Present
Independent Board Director at
Sporos Bioventures
October 2021 - Present
Independent Board Director at
Xilio Therapeutics, Inc.
September 2019 - June 2022
Chief Medical Officer at
Black Diamond Therapeutics
September 2020 - September 2021
Board Director and Chief Medical Officer at
Treadwell Therapeutics, Inc.
January 2020 - May 2020
Head Of Research And Development at
TIO Bioventures
January 2020 - May 2020
SVP, Chief Medical Officer at
CytomX Therapeutics
August 2015 - September 2019
Member Board of Directors at
CytomX Therapeutics
March 2015 - August 2015
Vice President, Head of Immuno-Oncology at
Eli Lilly and Company
May 2015 - August 2015
SVP, Head of Immuno-Oncology at
AstraZeneca
November 2013 - December 2014
Chief Medical Officer at
Mirati Therapeutics
January 2012 - September 2013
Vice President, Development Lead, Immuno-oncology at
Bristol Myers Squibb
September 2004 - January 2012
Executive Director, Global Research and Development at
Bristol Myers Squibb
May 2003 - September 2004
Director, Global Clinical Leader, R & D at
Bayer
January 1997 - May 2003
Rachel Humphrey Md
Education
The Johns Hopkins University School of Medicine, Residency
January 1989 - January 1992
Case Western Reserve University School of Medicine, Md
January 1985 - January 1989
January 1979 - January 1983
Frequently Asked Questions about Rachel Humphrey Md
What is Rachel Humphrey Md email address?
Rachel Humphrey Md's primary email address is ***************@normunity.com. To view the full verified email and additional contact details, sign up for free with Muraena.
What company does Rachel Humphrey Md work for?
Rachel Humphrey Md is a Independent Board Director at HotSpot Therapeutics, Inc., a company specializing in Commercial physical research.
Where Rachel Humphrey Md graduated from?
Rachel Humphrey Md holds a degree in Internal Medicine from The Johns Hopkins University School of Medicine.
How can I directly contact Rachel Humphrey Md?
To contact Rachel Humphrey Md directly, you can use the email address ***************@normunity.com. Complete contact information is available upon registration with Muraena.
Who is Rachel Humphrey Md?
Rachel Humphrey, MD, is a distinguished pharmaceutical executive with over 18 years of experience in product development and clinical research, particularly in oncology and immuno-oncology. As the President and Founding CEO of Normunity, she has a proven track record in leading teams to successfully develop and commercialize new molecular entities, including the renowned drugs NEXAVAR and YERVOY. Rachel has held significant leadership roles at major pharmaceutical companies such as AstraZeneca and Bristol Myers Squibb, where she has been instrumental in shaping product strategies and overseeing global development programs. Her expertise spans from early-stage clinical trials to post-launch activities, and she has extensive experience in regulatory interactions and alliance management. Rachel's academic background includes a medical degree from Case Western Reserve University and a residency at Johns Hopkins University, underscoring her deep commitment to medical science. She is also known for her strategic insights and ability to foster collaborations between large and small biotech firms, contributing to advancements in cancer treatment.
Rachel`s contact details
***************@normunity.com
*********@pyxisoncology.com
*********@cytomx.com
Colleagues
Chief Business Officer
Chief Operating Officer
Vice President, Development Operations
Senior Vice President
Co-Founder and Chief Scientific Officer
Vice President and Head, Translational Sciences and Clinical Biomarkers
Vice President, Accounting and Corporate Controller
Vice President Corporate Strategy
SVP, Head of Immunology
Executive Director, Chemical Biology